No recent news impacting the business model or operations was available at the time of this report.

The company benefits from a management team with deep healthcare industry expertise and a broad network, which may facilitate sourcing attractive acquisition targets. Its focus on healthcare services and technology aligns with favorable industry dynamics and potential growth opportunities. The substantial IPO proceeds held in trust provide capital to pursue meaningful business combinations. The company's structured acquisition criteria and due diligence process aim to identify targets with strong management and growth potential, potentially enabling value creation for shareholders post-combination.

The company currently has no operating revenue and has incurred losses since inception, relying on capital markets and loans for funding. Its liquidity position as of September 30, 2026, shows a current ratio below 1, indicating potential short-term financial constraints. The company is subject to NYSE listing requirements and is currently under a compliance plan due to insufficient public shareholders, with risk of delisting if standards are not met. Conflicts of interest among management and affiliated entities may limit acquisition opportunities. The success of the business model depends on completing a suitable business combination, which carries execution risk and uncertainty.

As a blank check company, Jackson Acquisition Co II's moat is primarily derived from its management team's extensive experience and network in the healthcare sector, which supports sourcing and executing acquisition opportunities. The company's ability to leverage relationships with healthcare operators, investment bankers, and advisors provides access to potential targets. Its focus on acquiring businesses with strong management teams, growth potential, and public market readiness aims to create value post-combination. However, as a SPAC without operating assets or revenue, its competitive advantage depends heavily on management execution and successful identification of suitable acquisition targets.

• NYSE Listing Compliance Risk: The company is currently not in compliance with the NYSE requirement of having at least 300 public shareholders and is under a plan period until August 6, 2027, to regain compliance. Failure to meet listing standards could result in delisting, reducing liquidity and market access.
• Liquidity Constraints: As of September 30, 2026, the company reported a current ratio of 0.47, indicating current liabilities exceed current assets, which may constrain operational flexibility prior to completing a business combination.
• Conflict of Interest Risks: Management and directors have fiduciary duties and contractual obligations to affiliated entities, which may compete for acquisition opportunities and limit the company's ability to pursue certain targets.
• Execution Risk of Business Combination: The company's success depends on identifying and completing a suitable business combination. There is no assurance that a target will be found or that the combination will be successful.

• Jackson Acquisition Co II is a blank check company incorporated in the Cayman Islands on September 11, 2024, formed to complete a business combination with one or more businesses or entities.
• The company focuses its search on high-quality businesses primarily in healthcare services, healthcare technology, or the healthcare industry, but is not restricted to healthcare.
• The company completed its IPO on December 11, 2024, issuing 23 million units at $10.00 each, raising gross proceeds of $230 million, plus a private placement raising $8.4 million, with proceeds held in a trust account.
• Management has broad discretion over the use of IPO proceeds, primarily intended for consummating a business combination and working capital.
• The company has no current revenue and has incurred losses since inception, funding operations through securities sales and loans from sponsors.
• The Class A ordinary shares and rights trade on the NYSE under symbols JACS and JACS.R respectively, with units trading as JACS.U.
• The management team and board have extensive experience in operating companies, corporate strategy, growth, sales networks, strategic investments, acquisitions, capital markets, and fostering relationships in healthcare.
• The acquisition strategy leverages management's network in healthcare and related industries, focusing on companies with favorable industry dynamics, strong management teams, growth potential, clear value propositions, and readiness for public markets.
• The company conducts thorough due diligence on prospective targets, including management meetings, document reviews, and operational assessments.
• The company may pursue business combinations with affiliated entities but requires independent fairness opinions in such cases.
• Management and directors may have conflicts of interest due to relationships with sponsor entities and other obligations, which may affect acquisition opportunities.
• The initial business combination must meet NYSE listing rules, including an 80% fair market value test of assets held in trust, and must be approved by a majority of independent directors.
• The company is an emerging growth company and a smaller reporting company, eligible for certain reduced disclosure obligations under the JOBS Act.
• As of September 30, 2026, the company reported current assets of $340,627 and current liabilities of $727,081, resulting in a current ratio of 0.47 and a cash ratio of 0.
• Net income reported for the period ending September 30, 2026, was $1,996,366.
• Basic and diluted earnings per share were reported as -$0.01 for the period ending September 30, 2024.
• The company received a notice from the NYSE on February 6, 2026, for non-compliance with the 300 public shareholders requirement but submitted a plan accepted by the NYSE on April 29, 2026, allowing continued listing subject to conditions and progress.
• Failure to regain compliance with NYSE listing standards could lead to delisting, which would have material adverse consequences including reduced liquidity and trading restrictions.